Skip to main content
PET tracer from RadioMedix, Curium gets FDA fast-track status

The FDA granted fast-track status to RadioMedix and Curium's Cu-64 DOTATATE, a PET tracer for diagnosing neuroendocrine tumors. A late-stage trial for the agent has been completed, and a new drug application is expected to be submitted to the FDA this year.

Full Story: